Clinical Trial

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.
Protocol Amendment History 36 amendments
This ClinicalTrials.gov record has been amended 36 times since 2024-08-19; most recent amendment 2026-05-14.
Status change: Recruiting → Active, Not Recruiting 2025-12-02
Status change: Not Yet Recruiting → Recruiting 2024-09-17
Trial Details
NCT Number NCT06564142
Lead Sponsor Alpine Immune Sciences Inc, A Subsidiary of Vertex
Conditions Immunoglobulin A Nephropathy
Enrollment 605 participants
Start Date 2024-08-30
Primary Completion 2028-01-30 (estimated)
Study Completion 2028-01-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-15